bioMérieux - First-Half Results at June 30, 2011

06 September, 2011

The Board of Directors of bioMerieux, a world leader in the field of in vitro diagnostics, met today to approve the consolidated financial statements for the six months ended June 30, 2011. The meeting was chaired by Jean-Luc Belingard and attended by the Statutory Auditors, who had performed a limited review of the financial statements.

Operating income before non-recurring items

  • Up 5.2%
  • At 17.8% of sales

Two strategic acquisitions

  • AES Laboratoire, making bioMerieux world leader in food testing
  • ARGENE, specialized in molecular diagnostics for immunocompromised patients

 

Pioneering Diagnostics